Uricosuric drugs

Detailed mechanism of action at the nephron level

Drugs of this group, prominent representatives of which are sulfinpyrazone and probenecid, exert their pharmacological effect directly in the renal tissues. Their molecules enter into direct competition with uric acid molecules for binding to specific transport systems located in the renal tubules.

As a result of this competitive interaction, a reliable blockade of urate reabsorption (reuptake) occurs, predominantly in the distal nephron segments. Uric acid loses its ability to return to the systemic circulation and, consequently, there is a sharp increase in its excretion with urine.

A special place in the classification is held by benzbromarone, a drug characterized as a specific uricosuric agent. Its mechanism of action differs somewhat:

• It purposefully blocks a specific enzyme system in the renal tubular epithelium.
• This system normally regulates the exchange of anions and uric acid.
• Suppression of its activity leads to a pronounced decrease in reabsorption.

In clinical practice, benzbromarone is quite often prescribed not as monotherapy, but in a well-considered combination with allopurinol to achieve optimal control over urate levels.

Potential therapy risks and preventive measures

The pharmacodynamics of uricosuric drugs harbors a serious danger directly stemming from their mechanism of action. Intensive urate excretion naturally leads to a sharp increase in uric acid concentration directly within the renal filtrate. Such oversaturation of the solution creates a direct threat of substance crystallization. The precipitation of crystals is the first stage in the formation of calculi (stones) in the urinary tract.

Strict prevention is required to prevent this formidable complication. Patients are invariably prescribed:

1. Abundant fluid intake for mechanical dilution of urine.
2. Intake of specialized urine-alkalinizing agents (a typical example being potassium citrate).

In addition to nephrological risks, therapy may be accompanied by a number of systemic adverse effects. Dyspeptic disorders manifesting as nausea and abdominal pain are frequently reported from the gastrointestinal tract. The most severe complication is the hematotoxicity of the drugs. It can manifest as various cytopenias: from anemia and thrombocytopenia to life-threatening conditions such as leukopenia and agranulocytosis.

Drug interactions in comorbid patients

The prescription of uricosuric drugs requires heightened vigilance from the physician when managing comorbid patients receiving concomitant pharmacotherapy. Drugs in this group are capable of entering into clinically significant interactions, altering the efficacy of other medications.

Potentiation (enhancement of pharmacological action) Uricosuric drugs can dangerously enhance the effects of a number of vital medications. Careful monitoring of the following groups is required when administered concomitantly:

• Anticoagulants and antiplatelet agents.
• Fibrinolytic drugs.
• Hypoglycemic agents.

Antagonism (weakening of the uricosuric effect) The therapeutic effect of the uricosuric drugs themselves can be significantly reduced or completely nullified under the influence of certain substances. Alcohol consumption leads to pronounced antagonism. Furthermore, the uricosuric effect is critically weakened by the concurrent intake of certain diuretics, primarily thiazide diuretics and ethacrynic acid.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Pharmacokinetics of sulfinpyrazone and probenecid
• Mechanisms of hematotoxicity of uricosuric drugs
• Rationale for combination therapy with benzbromarone and allopurinol
• The role of potassium citrate in the prevention of urate nephrolithiasis
• Clinical significance of interaction with hypoglycemic agents

Other topics in the section "Antigout drugs"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.